艾普拉唑与奥美拉唑分别联合瑞巴派特治疗消化性溃疡的效果比较

Comparison on effects of esomeprazole and omeprazole in the combined treatment with rebamipide for peptic ulcer

目的探讨瑞巴派特分别联合艾普拉唑、奥美拉唑在消化性溃疡中的治疗效果。方法选择2016年1月至2018年5月运城市盐湖区人民医院收治的消化性溃疡患者112例,采用随机数表法将患者分为两组,每组56例。对照组给予艾普拉唑联合瑞巴派特治疗,观察组给予奥美拉唑联合瑞巴派特治疗。比较两组溃疡愈合质量、不良反应发生情况、幽门螺杆菌(Hp)根除率及临床治疗效果。结果治疗后两组各溃疡愈合质量因子评分均有所降低,差异有统计学意义(P<0.05);且观察组各溃疡愈合质量因子评分均低于对照组,但差异未见统计学意义(P>0.05)。两组不良反应发生率、Hp根除率及临床治疗总有效率比较,差异未见统计学意义(P>0.05)。结论艾普拉唑、奥美拉唑分别与瑞巴派特联合应用均可在消化性溃疡患者治疗中发挥重要作用,临床可根据实际情况对药物进行合理应用。

Objective To investigate the therapeutic effect of esomeprazole and omeprazole in the combined treatment with rebamipide for peptic ulcer.Methods A total of 112 patients with peptic ulcer patients admitted to Yanhu District People’s Hospital of Yuncheng from January 2016 to May 2018 were selected.And they were divided into two groups by random number table method,with 56 cases in each group.Patients in control group were treated with esomeprazole combined with rebamipide,while patients in observation group were treated with omeprazole combined with rebamipide.The quality of ulcer healing,adverse reactions,Helicobacter pylori(Hp)eradication rate and clinical treatment effect were compared between the two groups.Results After treatment,the scores of quality factors of ulcer healing were decreased in the two groups,and the differences were statistically significant(P<0.05).Compared with control group,the scores of quality factors of ulcer healing were slightly lower in observation group after treatment,but the differences were not statistically significant(P>0.05).The incidence of adverse reactions,eradication rate of Hp and total effective rate of clinical treatment in obervation group did not significantly differ from those in control group(P>0.05).Conclusions Esomeprazole and omeprazole in combination with rebamipide both play important roles in the treatment of peptic ulcer.Clinicians should formulate protocol of drug according to actual condition.